'Hidden' breast cancer found in new screening study
A pioneering breast cancer trial involving more than 9,000 patients has found early stages of the disease that might be missed by regular mammograms.
Researchers used a range of different scanning methods, including MRI scans and injecting dye into breast tissue, to better understand the disease.
More than 1,300 patients in the trial were recruited through Gloucestershire Hospitals NHS Trust.
Dr Sarah Vinnicombe, the lead breast radiologist and deputy director of screening at the Thirlestaine Breast Centre in Cheltenham, said she and her colleagues had known for a long time that mammography "even though it's a good screening tool for most women, is not perfect".
The issue, she told BBC Radio Gloucestershire, comes down to the density of breast tissue.
People with denser tissue are at a higher risk of developing cancer, but as breast tissue and cancers both appear white on mammograms, early warning signs can be difficult to pick up.
The researchers looked at three different ways of picking up early-stage cancers - a whole-breast ultrasound, a quick form of breast MRI and a type of mammogram in which patients are injected with a dye to highlight abnormal areas.
With more than 9,000 women involved overall it was the first study ever to take this approach and, Dr Vinnicombe said, it yielded "fascinating" results.
What the researchers found in the group of patients who had the MRI scan or contrast mammogram was a "massive increase in the number of cancers" detected.
As for how their findings could impact what women are offered, Dr Vinnicombe said: "There are a lot of conversations going on in the Department of Health and the national screening committee at the moment.
"It's a work in progress - it's quite clear that we can't just implement contrast mammography or MRI for all those women in the country who have very dense breasts," she added, as this would amount to around 10% of the 2.2 million women screened each year.
However, she added, the research had found that not all women with denser breast tissue were at higher risk - meaning the more effective techniques they had identified could be targeted at a smaller group of women.
Follow BBC Gloucestershire on Facebook, X and Instagram. Send your story ideas to us on email or via WhatsApp on 0800 313 4630.
New hope for patients with breast cancer gene
Call for NHS to give women with dense breasts extra cancer scans
Gloucestershire NHS Foundation Trust
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
19 hours ago
- Medscape
MRI-Led Surveillance Stratifies Prostate Cancer Risk
In a cohort study of patients with prostate cancer, MRI-led risk-adapted active surveillance demonstrated effectiveness in risk stratification. The approach showed that MRI visibility and the presence of secondary Gleason pattern 4 at baseline were associated with higher rates of progression and treatment initiation. METHODOLOGY: Researchers analysed 1150 patients who started active surveillance between February 2000 and July 2023, including those with a Gleason score (GS) ≤ 3 + 4, prostate-specific antigen (PSA) < 20 ng/mL, and at least two MRI scans. Participants underwent PSA testing three to four times in the first year, followed by biannual testing; MRI was performed at baseline and 12 months, with an additional MRI scan performed at 24 months for those with MRI-visible lesions at baseline. Patients were stratified into four groups on the basis of baseline risk factors, including GS (3 + 3 vs 3 + 4) and MRI visibility ("non-visible disease" vs "visible disease"). The primary outcome was event-free survival, with an event defined as the detection of GS ≥ 4 + 3 or the initiation of any prostate cancer treatment. The median follow-up duration was 64 months per person overall and 72 months for 732 patients without an event. At baseline, 64% of patients had GS 3 + 3 and 36% had GS 3 + 4; 49% of those with GS 3 + 4 had MRI-visible disease. TAKEAWAY: Event-free survival rates varied significantly on the basis of the risk group, with 5-year rates of 91% for non-visible GS 3 + 3, 71% for MRI-visible GS 3 + 3, 71% for non-visible GS 3 + 4, and 44% for MRI-visible GS 3 + 4 disease. Among 487 patients who underwent follow-up biopsies, histological upgrade to GS ≥ 4 + 3 occurred in 67 patients; non-visible GS 3 + 3 cases had 5- and 10-year rates of 1.2% and 6.1%, respectively, for histological progression to GS ≥ 4 + 3, while the rates were 17% and 43% for those with MRI-visible GS 3 + 4 disease at baseline, respectively. Progression to nodal or bone metastases was observed in 10 patients, occurring only in those who had declined recommended follow-up MRI and/or biopsies. The 10-year rate of commencing treatment was 28% for those with non-visible GS 3 + 3 disease vs 85% for those with MRI-visible GS 3 + 4 disease and 46% for those with non-visible GS 3 + 4 disease vs 54% for those with MRI-visible GS 3 + 3 disease. IN PRACTICE: "Results from our cohort suggest that AS [active surveillance] patients can be monitored safely with MRI, and the decision to biopsy was based on MRI findings and PSA changes. Prospective, multicentre, clinical trials are required and currently being designed to further evaluate this approach," the authors wrote. SOURCE: This study was led by Cameron Englman, Division of Surgery & Interventional Science, University College London, London, England. It was published online on May 27, 2025, in European Urology . LIMITATIONS: Compared with time-based biopsy protocols, the MRI-led risk-adapted approach may underestimate histological progression. Additionally, as a cohort study without a strict protocol, practice evolved alongside contemporary pathology and radiology standards, with MRI quality, reporting standards, and the definition of radiological progression varying over time, particularly improving after the adoption of the PRECISE recommendations in 2016. DISCLOSURES: This study did not receive any specific funding. Several authors reported receiving consulting fees and grants and having other ties with various sources.
Medscape
19 hours ago
- Medscape
Radiology Workforce Shortages Impacting Cancer Care
A chronic shortage of radiologists and oncologists is putting patients in the UK at risk, a new report found. The annual workforce census by the Royal College of Radiologists (RCR) warned that the safe delivery of NHS cancer care is becoming 'increasingly impossible' due to an escalating shortfall of doctors coupled with rising demand for care. In 2024, the UK had a 29% shortfall of clinical radiologists, with regional gaps ranging from 25% in Scotland to 32% in Wales. The workforce grew by 4.7% that year — less than in 2023, when it increased by 6.3%. The college forecasts the radiologist shortfall will reach 39% by 2029. Oncology Under Strain Clinical oncologists are also in short supply, with a current 15% gap expected to rise to 19% by 2029. This is despite a 5.4% increase in the workforce in 2024—the strongest growth since 2018. The RCR reported that 23% of cancer centres were experiencing recruitment freezes, making it harder to meet growing demand. Demand Continues to Outpace Capacity The shortages threaten the government's plans to cut waiting times and improve cancer outcomes. In 2024, demand for computerised tomography (CT) and magnetic resonance imaging (MRI) grew by 8%, but workforce growth did not keep pace. Every radiology leader surveyed last year reported delays to diagnostic scans caused by staff shortages. Nine in 10 radiology team leaders reported that patients were waiting longer to start treatment, while seven in 10 expressed concern that staff shortages were putting patient safety at risk – down slightly from 85% in 2023. Chronic problems such as workforce shortages, reporting backlogs, and staff vacancies remain too high, according to Dr Robin Proctor, the RCR's m edical director responsible for professional practice and clinical radiology. Consultants Leaving Earlier Staff retention is worsening, with experienced consultants leaving the NHS at younger ages. In 2024, the median age of consultant clinical radiologists leaving the NHS workforce was 50 – down from 56 in 2020. Four in five (79%) of leavers were under 60, and two in five (42%) were under 45. Clinical oncologists followed a similar trend. Their median exit age dropped to 54, from 57 in 2023 and 59 in 2022. Nearly 76% of leavers were under 60, and 26% were under 45. One consultant clinical oncologist told the college that delays in scans and treatment were resulting in missed or late cancer diagnoses. Some patients' conditions were deteriorating or reaching a stage where treatment was no longer possible. Changing Work Practices 'Working conditions and ways of working need to change if we are to address this problem and meet the growing demand for our expertise,' Proctor said. The RCR has called on the government to invest in training and recruitment. In 2024, the NHS spent an estimated £325 million on temporary radiology staff. The cost of outsourcing had doubled since before the COVID-19 pandemic and had surged by almost a quarter in the past year. The RCR estimated that increasing radiology trainee numbers by 50% could eliminate three-quarters of the current shortfall and save the NHS £460 million over the next 10 years. 'Patients are being failed by a chronic lack of radiologists and oncologists,' said RCR president Dr Katharine Halliday. 'The longer we delay action, the worse it gets,' she added.
Yahoo
a day ago
- Yahoo
Lack of doctors causing cancer delays
A senior radiologist has said there are not enough doctors to keep up with the number of cancer patients needing scan results, diagnosis and treatment. Dr Tom Roques, vice president of clinical oncology at the Royal College of Radiologists, who also works at Norwich and Norfolk University Hospital, claimed the NHS was struggling to meet the government's 62-day diagnosis targets in cancer care. However, Steffan Aquarone, North Norfolk MP, believed another significant challenge was ensuring patients in rural areas could access treatment. A spokesman for the Department of Health and Social Care said: "We are determined to tackle delays, diagnose cancer earlier and treat it faster." Dr Roques described a shortage of both radiologists and doctors. He said: "People are waiting for scan results or waiting for diagnoses and we're also really short of cancer doctors. "There are delays further down the line in actually having that treatment because there aren't enough people to provide it." However, he says the problem was not just a Norfolk issue. "We are just not able to meet the government-set targets which themselves, are not that ambitious really. "If you don't have the staff and nurses and the physical space to treat them [patients] then people are not going to be able to have the treatment they deserve." Matt Sample, from Cancer Research UK, said the 62-day government target had been missed annually since 2015, with 74,000 people not beginning treatment within that target last year. He said: "For people affected by cancer, every single day waiting to get that diagnosis and begin treatment is a worrying and stressful time even when they are seen within targets. "When those targets are missed, those worries and stresses are just compounded - it can impact their treatment options and ultimately their outcomes. Liberal Democrat Aquarone agreed, saying "more people die than are necessary". He remains concerned about the ability of people in rural areas to get cancer care. "This is entirely about access to treatment," he said. Julie Keeling, nurse director for planned care at Norwich and Norfolk University Hospital, said: "Our latest validated figures show that as of March 2025, 51.8 % of patients receiving first treatment for cancer are treated by day 62, with 48.2 % of patients waiting over 62 days for first cancer treatment. It is encouraging that this is an improvement on previous data. "We know that we have more to do and are sorry that some patients have had to wait longer than expected to see us following a cancer referral." The Department of Health and Social Care said: "We are delivering 40,000 more appointments every week, investing £1.5bn in both new surgical hubs and AI scanners, rolling out cutting-edge radiotherapy machines to every region in the country and backing our radiologists and oncologists with above inflation pay rises for the second year in a row." Follow Norfolk news on BBC Sounds, Facebook, Instagram and X. Cancer patient's treatment was delayed - coroner Hospital praised for breast cancer surgery wait time Hospital has second-longest waiting time for care NHS struggling to provide safe cancer care, say doctors Department of Health and Social Care Norwich and Norfolk University Hospital NHS Foundation Trust Cancer Research UK
